Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
Building a liver transplant program in a resource limited country: a 15-year retrospective analysis of 648 patients operated in the Romanian National Program
Background: Liver transplantation (LT) has become an established treatment for end-stage liver disease, with more than 20.000 procedures yearly worldwide. The aim of this study was to analyze the results of Romanian National Program of LT after 15 years of activity.
Methods: Between April 2000 and April 2015, 648 pts received 678 LTs in Romania. Male female ratio was 382 266, while adult pediatric ratio was 588 60, with a mean age of 45 years (median 50 yrs; range 7 months 68 yrs). Main LT indications were HBV-related cirrhosis (176 pts; 27.1%), hepatocellular carcinoma (128 pts; 19.7%), and HCV-related cirrhosis (118 pts; 18.2%).
Waiting time and indications for LT, patient and donor demographics, graft features, surgical procedures, and short and long-term outcomes were analyzed.
Results: DDLT was performed in 532 pts (82.1%): whole LT in 512 pts (79%), split LT in 16 pts (2.5%), reduced LT in 2 pts (0.3%), and domino LT in 2 pts (0.3%). LDLT was performed in 116 pts (17.9%): right hemiliver in 78 pts (12%), left lateral section in 26 pts (4%), left hemiliver in 7 pts (1.1%), left hemiliver with segment 1 in 3 pts (0.4%), and dual graft LDLT in 2 pts (0.3%).
Overall major morbidity rate was 43.8% (284 pts), while perioperative mortality was 7.9% (51 pts). Retransplantation rate was 4.6% (30 pts): 23 whole LTs, 3 reduced LTs, 3 split LTs, and 1 LDLT. Long-term overall 1-, 3-, and 5-year estimated survival rates for patients were 88.8%, 82.5%, and 79.2%, respectively, while for transplanted grafts were 77.9%, 71.6%, and 68.8%, respectively (p<0.001). Median waiting time for LT decreased significantly over time: from 107, 99, 51, and 45 months to 28, 18, 34, and 20 months in case of 0I, AII, BIII, and ABIV group pts, respectively. One-year overall mortality on waiting list also decreased significantly over time from 31.4% to 11.8%.
Conclusions: The liver transplantation program in Romania addresses all causes of acute and chronic liver failure or liver tumors in adults and children, using all surgical techniques.
Full Text Sources:
Abstract:
Views: 3644
Methods: Between April 2000 and April 2015, 648 pts received 678 LTs in Romania. Male female ratio was 382 266, while adult pediatric ratio was 588 60, with a mean age of 45 years (median 50 yrs; range 7 months 68 yrs). Main LT indications were HBV-related cirrhosis (176 pts; 27.1%), hepatocellular carcinoma (128 pts; 19.7%), and HCV-related cirrhosis (118 pts; 18.2%).
Waiting time and indications for LT, patient and donor demographics, graft features, surgical procedures, and short and long-term outcomes were analyzed.
Results: DDLT was performed in 532 pts (82.1%): whole LT in 512 pts (79%), split LT in 16 pts (2.5%), reduced LT in 2 pts (0.3%), and domino LT in 2 pts (0.3%). LDLT was performed in 116 pts (17.9%): right hemiliver in 78 pts (12%), left lateral section in 26 pts (4%), left hemiliver in 7 pts (1.1%), left hemiliver with segment 1 in 3 pts (0.4%), and dual graft LDLT in 2 pts (0.3%).
Overall major morbidity rate was 43.8% (284 pts), while perioperative mortality was 7.9% (51 pts). Retransplantation rate was 4.6% (30 pts): 23 whole LTs, 3 reduced LTs, 3 split LTs, and 1 LDLT. Long-term overall 1-, 3-, and 5-year estimated survival rates for patients were 88.8%, 82.5%, and 79.2%, respectively, while for transplanted grafts were 77.9%, 71.6%, and 68.8%, respectively (p<0.001). Median waiting time for LT decreased significantly over time: from 107, 99, 51, and 45 months to 28, 18, 34, and 20 months in case of 0I, AII, BIII, and ABIV group pts, respectively. One-year overall mortality on waiting list also decreased significantly over time from 31.4% to 11.8%.
Conclusions: The liver transplantation program in Romania addresses all causes of acute and chronic liver failure or liver tumors in adults and children, using all surgical techniques.
Full Text Sources:
Abstract:
Views: 3644
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Dec 2025
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.